|
1
|
Kuthi L, Jenei A, Hajdu A, Németh I, Varga
Z, Bajory Z, Pajor L and Iványi B: Prognostic factors for renal
cell carcinoma subtypes diagnosed according to the 2016 WHO renal
tumor classification: A study involving 928 patients. Pathol Oncol
Res. 23:689–698. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oto A, Herts BR, Remer EM and Novick AC:
Inferior vena cava tumor thrombus in renal cell carcinoma: Staging
by MR imaging and impact on surgical treatment. AJR Am J
Roentgenol. 171:1619–1624. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grignon DJ and Che M: Clear cell renal
cell carcinoma. Clin Lab Med. 25:305–316. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGuire A, Brown JA and Kerin MJ:
Metastatic breast cancer: The potential of miRNA for diagnosis and
treatment monitoring. Cancer Metastasis Rev. 34:145–155. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Romero-Cordoba SL, Salido-Guadarrama I,
Rodriguez-Dorantes M and Hidalgo-Miranda A: miRNA biogenesis:
Biological impact in the development of cancer. Cancer Biol Ther.
15:1444–1455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rocci A, Hofmeister CC and Pichiorri F:
The potential of miRNAs as biomarkers for multiple myeloma. Expert
Rev Mol Diagn. 14:947–959. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Leung AK and Sharp PA: microRNAs: A
safeguard against turmoil? Cell. 130:581–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leung WK, He M, Chan AW, Law PT and Wong
N: Wnt/β-catenin activates MiR-183/96/182 expression in
hepatocellular carcinoma that promotes cell invasion. Cancer Lett.
362:97–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang H, Bian Y, Tu C, Wang Z, Yu Z, Liu Q,
Xu G, Wu M and Li G: The miR-183/96/182 cluster regulates oxidative
apoptosis and sensitizes cells to chemotherapy in gliomas. Curr
Cancer Drug Targets. 13:221–231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang CL, Zheng XL, Ye K, Ge H, Sun YN, Lu
YF and Fan QX: MicroRNA-183 acts as a tumor suppressor in human
non-small cell lung cancer by down-regulating MTA1. Cell Physiol
Biochem. 46:93–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou Y, Chen Y, Ding W, Hua Z, Wang L, Zhu
Y, Qian H and Dai T: LncRNA UCA1 impacts cell proliferation,
invasion, and migration of pancreatic cancer through regulating
miR-96/FOXO3. IUBMB Life. 70:276–290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, Ma G, Liu J and Zhang Y:
MicroRNA-182 promotes proliferation and metastasis by targeting
FOXF2 in triple-negative breast cancer. Oncol Lett. 14:4805–4811.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang
Q, Cheng P, Tang ZH and Huang F: Meta-analysis of microRNA-183
family expression in human cancer studies comparing cancer tissues
with noncancerous tissues. Gene. 527:26–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa
P, Gui Y and Cai Z: Synthetic miRNA-mowers targeting miR-183-96-182
cluster or miR-210 inhibit growth and migration and induce
apoptosis in bladder cancer cells. PLoS One. 7:e522802012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Falzone L, Scola L, Zanghì A, Biondi A, Di
Cataldo A, Libra M and Candido S: Integrated analysis of colorectal
cancer microRNA datasets: Identification of microRNAs associated
with tumor development. Aging (Albany NY). 10:1000–1014. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Anwar SL, Krech T, Hasemeier B, Schipper
E, Schweitzer N, Vogel A, Kreipe H, Buurman R, Skawran B and
Lehmann U: hsa-mir-183 is frequently methylated and related to poor
survival in human hepatocellular carcinoma. World J Gastroenterol.
23:1568–1575. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Luo F, Li Q, Xu M, Feng D, Zhang G
and Wu W: Identification of new aberrantly expressed miRNAs in
intestinal-type gastric cancer and its clinical significance. Oncol
Rep. 26:1431–1439. 2011.PubMed/NCBI
|
|
20
|
Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X
and Tang H: MicroRNA-182 targets cAMP-responsive element-binding
protein 1 and suppresses cell growth in human gastric
adenocarcinoma. FEBS J. 279:1252–1260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song C, Zhang L, Wang J, Huang Z, Li X, Wu
M, Li S, Tang H and Xie X: High expression of microRNA-183/182/96
cluster as a prognostic biomarker for breast cancer. Sci Rep.
6:245022016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Q, Ren W, Huang B, Yi L and Zhu H:
MicroRNA-183/182/96 cooperatively regulates the proliferation of
colon cancer cells. Mol Med Rep. 12:668–674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tutar Y: miRNA and cancer; computational
and experimental approaches. Curr Pharm Biotechnol. 15:4292014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang J and Zeng Y: Identification of
miRNA-mRNA crosstalk in pancreatic cancer by integrating
transcriptome analysis. Eur Rev Med Pharmacol Sci. 19:825–834.
2015.PubMed/NCBI
|
|
25
|
Falzone L, Candido S, Salemi R, Basile MS,
Scalisi A, McCubrey JA, Torino F, Signorelli SS, Montella M and
Libra M: Computational identification of microRNAs associated to
both epithelial to mesenchymal transition and NGAL/MMP-9 pathways
in bladder cancer. Oncotarget. 7:72758–72766. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hafsi S, Candido S, Maestro R, Falzone L,
Soua Z, Bonavida B, Spandidos DA and Libra M: Correlation between
the overexpression of Yin Yang 1 and the expression levels of
miRNAs in Burkitt's lymphoma: A computational study. Oncol Lett.
11:1021–1025. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ito K and Murphy D: Application of ggplot2
to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol.
2:e792013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu SS, Quinn DI and Dorff TB: Clinical use
of cabozantinib in the treatment of advanced kidney cancer:
Efficacy, safety, and patient selection. Onco Targets Ther.
9:5825–5837. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Coppin C, Kollmannsberger C, Le L,
Porzsolt F and Wilt TJ: Targeted therapy for advanced renal cell
cancer (RCC): A Cochrane systematic review of published randomised
trials. BJU Int. 108:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van der Mijn JC, Mier JW, Broxterman HJ
and Verheul HM: Predictive biomarkers in renal cell cancer:
Insights in drug resistance mechanisms. Drug Resist Updat.
17:77–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rydzanicz M, Wrzesiński T, Bluyssen HA and
Wesoły J: Genomics and epigenomics of clear cell renal cell
carcinoma: Recent developments and potential applications. Cancer
Lett. 341:111–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xing T and He H: Epigenomics of clear cell
renal cell carcinoma: Mechanisms and potential use in molecular
pathology. Chin J Cancer Res. 28:80–91. 2016.PubMed/NCBI
|
|
35
|
He YH, Chen C and Shi Z: The biological
roles and clinical implications of microRNAs in clear cell renal
cell carcinoma. J Cell Physiol. 233:4458–4465. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ran L, Liang J, Deng X and Wu J: miRNAs in
prediction of prognosis in clear cell renal cell carcinoma. Biomed
Res Int. 2017:48329312017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ge YZ, Xu LW, Zhou CC, Lu TZ, Yao WT, Wu
R, Zhao YC, Xu X, Hu ZK, Wang M, et al: A BAP1 mutation-specific
MicroRNA signature predicts clinical outcomes in clear cell renal
cell carcinoma patients with wild-type BAP1. J Cancer. 8:2643–2652.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qiu M, Liu L, Chen L, Tan G, Liang Z, Wang
K, Liu J and Chen H: microRNA-183 plays as oncogenes by increasing
cell proliferation, migration and invasion via targeting protein
phosphatase 2A in renal cancer cells. Biochem Biophys Res Commun.
452:163–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu X, Wu J, Li S, Hu Z, Xu X, Zhu Y, Liang
Z, Wang X, Lin Y, Mao Y, et al: Downregulation of microRNA-182-5p
contributes to renal cell carcinoma proliferation via activating
the AKT/FOXO3a signaling pathway. Mol Cancer. 13:1092014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fan Y, Li H, Ma X, Gao Y, Bao X, Du Q, Ma
M, Liu K, Yao Y, Huang Q, et al: Dicer suppresses the malignant
phenotype in VHL-deficient clear cell renal cell carcinoma by
inhibiting HIF-2α. Oncotarget. 7:18280–18294. 2104.
|
|
41
|
Yu N, Fu S, Liu Y, Xu Z, Liu Y, Hao J,
Wang B and Zhang A: miR-96 suppresses renal cell carcinoma invasion
via downregulation of Ezrin expression. J Exp Clin Cancer Res.
34:1072015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li P, Sheng C, Huang L, Zhang H, Huang L,
Cheng Z and Zhu Q: MiR-183/−96/−182 cluster is up-regulated in most
breast cancers and increases cell proliferation and migration.
Breast Cancer Res. 16:4732014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Humphreys KJ, McKinnon RA and Michael MZ:
miR-18a inhibits CDC42 and plays a tumour suppressor role in
colorectal cancer cells. PLoS One. 9:e1122882014. View Article : Google Scholar : PubMed/NCBI
|
